Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Researchers discover breakthrough in ovarian cancer

15.02.2013
Findings from University of Arizona Cancer Center at St. Joseph's

Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.

The findings, published in the Feb. 14 edition of The Lancet Oncology, show that selumetinib targets a mutation in the MAPK pathway for patients with low-grade serous carcinoma, allowing for treatment on previously chemoresistant tumors.

"This is a potentially important breakthrough for the Gynecologic Oncology Group," said John Farley, MD, a gynecologic oncologist in the Division of Gynecologic Oncology and the Department of Obstetrics and Gynecology at the Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, a Dignity Health Member.

The Gynecologic Oncology Group is a non-profit international organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies.

Dr. Farley is part of the University of Arizona Cancer Center at St. Joseph's and is board certified in obstetrics and gynecology with a subspecialty certification in gynecologic oncology. He is a retired decorated Army colonel who completed a residency in obstetrics and gynecology and a fellowship in gynecologic oncology at Walter Reed Army Medical Center. He is the first author on this study.

This study was initially developed in 2007, with 52 patients enrolled for the Phase II clinical trial between December 2007 and November 2009. Patients were given 50 milligrams of selumetinib orally twice daily. Of those participants, eight had a measurable decrease in tumor size, seven had partial responses and 34 patients saw their tumors stabilize. The findings suggest that inhibitors of the MAPK pathway warrant further investigation in patients with low-grade ovarian cancer.

"There just aren't very good treatments for low-grade ovarian cancer, so this discovery opens up a lot of new exciting possibilities for us," Dr. Farley said. He added that Phase III of this trial is scheduled to begin in the next few weeks, with that trial to be the "definitive test" before the treatment becomes available to the general population.

This study is registered with ClinicalTrials.gov, number NCT00551070.

About The University of Arizona Cancer Center

The University of Arizona Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center headquartered in Arizona. The UACC is supported by NCI Cancer Center Support Grant number CA023074. With primary locations at the University of Arizona in Tucson and at St. Joseph's Hospital and Medical Center in Phoenix, the Cancer Center has more than a dozen research and education offices in Phoenix and throughout the state and 300 physician and scientist members work together to prevent and cure cancer. For more information, go to http://www.arizonacancercenter.org

About St. Joseph's Hospital and Medical Center

Located in the heart of Phoenix, Ariz., St. Joseph's Hospital and Medical Center is a 607-bed, not-for-profit hospital that provides a wide range of health, social and support services with special advocacy for the poor and underserved. St. Joseph's is a nationally recognized center for quality tertiary care, medical education and research. It includes the internationally renowned Barrow Neurological Institute, the Heart & Lung Institute, the Muhammad Ali Parkinson Center, and a Level I Trauma Center verified by the American College of Surgeons. U.S. News & World Report routinely ranks St. Joseph's among the best hospitals in the United States for neurology and neurosurgery.

Lynne Reaves | EurekAlert!
Further information:
http://www.arizonacancercenter.org
http://www.stjosephs-phx.org/index.htm

More articles from Health and Medicine:

nachricht New evidence: How amino acid cysteine combats Huntington's disease
27.07.2016 | Johns Hopkins Medicine

nachricht Cord blood outperforms matched, unrelated donor in bone marrow transplant
27.07.2016 | University of Colorado Anschutz Medical Campus

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrakompakter Photodetektor

Der Datenverkehr wächst weltweit. Glasfaserkabel transportieren die Informationen mit Lichtgeschwindigkeit über weite Entfernungen. An ihrem Ziel müssen die optischen Signale jedoch in elektrische Signale gewandelt werden, um im Computer verarbeitet zu werden. Forscher am KIT haben einen neuartigen Photodetektor entwickelt, dessen geringer Platzbedarf neue Maßstäbe setzt: Das Bauteil weist eine Grundfläche von weniger als einem Millionstel Quadratmillimeter auf, ohne die Datenübertragungsrate zu beeinträchtigen, wie sie im Fachmagazin Optica nun berichten. (DOI: 10.1364/OPTICA.3.000741)

Die neuentwickelten Photodetektoren, die weltweit kleinsten Photodetektoren für die optische Datenübertragung, eröffnen die Möglichkeit, durch integrierte...

Im Focus: Self-assembling nano inks form conductive and transparent grids during imprint

Transparent electronics devices are present in today’s thin film displays, solar cells, and touchscreens. The future will bring flexible versions of such devices. Their production requires printable materials that are transparent and remain highly conductive even when deformed. Researchers at INM – Leibniz Institute for New Materials have combined a new self-assembling nano ink with an imprint process to create flexible conductive grids with a resolution below one micrometer.

To print the grids, an ink of gold nanowires is applied to a substrate. A structured stamp is pressed on the substrate and forces the ink into a pattern. “The...

Im Focus: Neues Forschungsnetzwerk für Mikrobiomforschung

Mikroben und Viren haben weitreichenden Einfluss auf die Gesundheit von Mensch und Tier. Die neu gegründete "Austrian Microbiome Initiative" (AMICI) fördert die nationale Mikrobiomforschung und vernetzt MedizinerInnen und ForscherInnen verschiedenster Fachrichtungen zur Nutzung von Synergien.

Bakterien, Archaeen, Pilze, Viren – Milliarden von Mikroorganismen leben in Symbiose in und auf Menschen und Tieren. Diese mikroskopisch kleinen Lebewesen...

Im Focus: The Glowing Brain

A new Fraunhofer MEVIS method conveys medical interrelationships quickly and intuitively with innovative visualization technology

On the monitor, a brain spins slowly and can be examined from every angle. Suddenly, some sections start glowing, first on the side and then the entire back of...

Im Focus: Superschneller Internetfunk dank Terahertz-Strahlung

Wissenschaftler aus Dresden und Dublin haben einen vielversprechenden technologischen Ansatz gefunden, der Notebooks und anderen mobilen Computern in Zukunft deutlich schnellere Internet-Funkzugänge ermöglichen könnte als bisher. Die Teams am Helmholtz-Zentrum Dresden-Rossendorf (HZDR) und am irischen Trinity College Dublin brachten hauchdünne Schichten aus einer speziellen Verbindung von Mangan und Gallium dazu, sehr effizient Strahlung im sogenannten Terahertz-Frequenzbereich auszusenden. Als Sender in WLAN-Funknetzen eingesetzt, könnten die höheren Frequenzen die Datenraten zukünftiger Kommunikations-Netzwerke spürbar erhöhen.

„Wir halten diesen Ansatz für technologisch sehr interessant“, betont Dr. Michael Gensch, Leiter einer Arbeitsgruppe am HZDR, die sich mit den...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Wissenschaftsjahr Meere und Ozeane

27.07.2016 | Veranstaltungen

8. Forum Energie

26.07.2016 | Veranstaltungen

Kongress für Molekulare Medizin: Krankheiten interdisziplinär verstehen und behandeln

20.07.2016 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Ich packe meinen Koffer und nehme mit: Sonnenschutz und ein gutes Gewissen

27.07.2016 | Unternehmensmeldung

Intelligente Mobilität

27.07.2016 | Energie und Elektrotechnik

Neues Verfahren fügt Bleche besser zusammen

27.07.2016 | Verfahrenstechnologie